The fusion protein Arcalyst (rilonacept), an IL-1 trap that acts as a soluble decoy receptor, is also marketed by Regeneron Pharmaceuticals ... animals as drug bioreactors remains limited ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

Regeneron Pharmaceuticals announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for linvoseltamab, an investigational treatment for adult patients with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

LONG ISLAND, New York (WABC) -- Long Island is well represented this year at the prestigious Regeneron Science Talent Search. The annual search is the longest running of its kind, and seeks the ...

Alaina Pinto of The Wheatley School in East Williston School District was announced as one of the top 300 scholars from across the nation in the Regeneron Science Talent Search 2025, the nation ...

The first cohort of ATI trainees embarked on internships at Regeneron Pharmaceuticals in 2021, where Bob McCowan, SVP and CIO, welcomed them onto technical and IT teams. As one of the first ...